CJ’s Exone eyeing bigger market share
CJ Cheil Jedang is striving to expand its share of the domestic hypertension combination drug market dominated by international drugmakers.
Exone, CJ’s new incrementally modified drug (IMD) containing valsartan and amlodipine adipate, is expected to challenge Exforge of Novartis and Twynsta...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
